Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery
Background Perioperative antiplatelet agents potentially increase bleeding after non–ST‐segment elevation (NSTE) acute coronary syndromes (ACS). The protease‐activated receptor 1 antagonist vorapaxar reduced cardiovascular events and was associated with increased bleeding versus placebo in NSTE ACS,...
Main Authors: | Sean vanDiepen, Pierluigi Tricoci, Mohua Podder, Cynthia M. Westerhout, Philip E. Aylward, Claes Held, Frans Van de Werf, John Strony, Lars Wallentin, David J. Moliterno, Harvey D. White, Kenneth W. Mahaffey, Robert A. Harrington, Paul W. Armstrong |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2015-12-01
|
Series: | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease |
Subjects: | |
Online Access: | https://doi.org/10.1161/JAHA.115.002546 |
Similar Items
-
Vorapaxar
by: Gianluca Airoldi, et al.
Published: (2013-04-01) -
Perioperative management of patient with intracoronary stent presenting for noncardiac surgery
by: Indira Gurajala, et al.
Published: (2016-01-01) -
Antiplatelet therapy in patients with coronary artery stents for noncardiac surgery: Role of thromboelastography
by: Rashmi Jain, et al.
Published: (2011-01-01) -
Association between Intraoperative Hyperlactatemia and Myocardial Injury after Noncardiac Surgery
by: Jeayoun Kim, et al.
Published: (2021-09-01) -
Perioperative vascular events and myocardial injury after noncardiac surgery in vascular surgery: An overview of the current emerging evidence and guidelines
by: Alben Sigamani
Published: (2017-01-01)